Navigation Links
Better Ways Needed to Track Drug Safety: Report
Date:5/1/2012

TUESDAY, May 1 (HealthDay News) -- A management plan to gather, assess and respond to data about all medications' risks from the time they are approved until they are no longer on the market is needed to improve drug safety in the United States, says an Institute of Medicine report released Tuesday.

The U.S. Food and Drug Administration approves new drugs based on clinical trial evidence that their benefits outweigh their risks. However, the full range of a medication's effects may not become apparent until it is used by a larger, more diverse population over a long period of time, the FDA-sponsored report noted.

A number of drugs approved by the FDA were later found to have problems, including the pain reliever Vioxx, the diabetes drug Avandia and the cholesterol-lowering drug Crestor.

Report recommendations include:

  • The risk- and benefit-assessment and management plan for each drug should be a publicly available document that would gather data about the drug during its entire time on the market.
  • The document should describe known safety concerns at the time of the drug's approval or that become evident as it is used by consumers.
  • The document should also include all FDA regulatory actions taken on a drug, such as restrictions on its use or ordering a manufacturer to conduct further research after approval (postmarket research).

"It is not possible to know what the full range of a drug's benefits and risks will be until it is used by many different kinds of patients over time, so it is critical that FDA continues to monitor and learn about the effects of drugs after they are marketed," said report committee co-chair Ruth Faden, a professor of biomedical ethics and executive director of the Berman Institute of Bioethics, Johns Hopkins University, said in an Institute of Medicine news release.

The FDA already gathers much of this information but it is scattered across multiple records. Collecting this information in a single, publicly accessible format would show the FDA's commitment to this drug "life-cycle" approach and make the process more open, according to the report.

Among its other recommendations, the report also said the FDA should order postmarket studies only if: a regulatory decision cannot be made based on existing safety evidence; the research can sufficiently address concerns about a drug's benefit-risk balance to help lead to a regulatory decision; the results will be used to make a regulatory decision in a timely fashion; and the rights and interests of the research participants can be adequately protected.

In addition, the FDA should ensure that postmarket studies it orders are conducted in ways that are ethically and scientifically sound, the report said.

"Our report focuses on how the agency can be proactive so that situations in which a drug's benefit-risk profile becomes problematic can be detected earlier, and it details how FDA can get the additional information on a drug's safety in the most ethical and scientifically sound ways when questions arise," Faden noted in the news release.

Report committee co-chair Steven Goodman, associate dean for clinical and translational research at Stanford University School of Medicine, added: "We believe that the adoption of a life-cycle approach to drug approval and monitoring will help the agency strengthen its oversight, better tackle these complex decisions, and increase public confidence in the agency's ability to protect public health. This will become increasingly important as FDA looks for ways to safely expedite the drug-approval process."

More information

The U.S. Food and Drug Administration outlines how it manages drug safety issues.

-- Robert Preidt

SOURCE: Institute of Medicine, news release, April 30, 2012


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Autism-Related Hypersensitivity Better Understood
2. Developing guidelines for better reporting of health research
3. Hawaiian-shirt.net Offers 10 Tips To Beat The Winter Blues: Things You Can Do Right Now to Have a Better Day
4. Better care at any hour for palliative patients
5. Patients Do Better at Hospitals That Follow Stroke Guidelines
6. More Expensive Hospital Care May Not Mean Better
7. New MRI May Lead to Better Brain Pictures
8. Biological clock could be a key to better health, longer life
9. Why do physicians order costly CTs? Ultrasound yields better diagnosis, safer, less costly
10. BetterInvesting Magazine Releases May Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
11. New approach to immune cell analysis seen as first step to better distinguish health and disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Better Ways Needed to Track Drug Safety: Report
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... 24, 2016   Bay Area Lyme Foundation ... Dean Center for Tick Borne Illness , Harvard ... MIT Hacking Medicine, University of California, Berkeley, and ... the five finalists of Lyme Innovation , ... than 100 scientists, clinicians, researchers, entrepreneurs, and investors ...
(Date:6/24/2016)... , June 24, 2016 The Academy ... of recommendations that would allow biopharmaceutical companies ... with entities that make formulary and coverage decisions, a ... "value" of new medicines. The recommendations address ... not appear on the drug label, a prohibition that ...
Breaking Medicine Technology: